Salubris Biotherapeutics Raises $35M in Funding

Salubris Biotherapeutics, a Gaithersburg, MD-based clinical-stage biotechnology company developing novel biologic therapeutics, raised $35M in funding.

Shenzhen Salubris committed additional funding to continue research and development of novel, complex biologics.

The company intends to use the funds to expand its continued research and development of clinical and pre-clinical programs.

Founded in August 2016 as a wholly-owned subsidiary of China-based pharmaceutical company Shenzhen Salubris Pharmaceuticals Co. Ltd., and led by CEO Sam Murphy, SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing complex biologics for cardiovascular, oncology, and neurodegenerative diseases.

The company also provided progress updates for JK07, the first investigational antibody fusion protein for heart failure, JK08, the first investigational IL15-CTLA4 antibody fusion for solid tumors and JK06, a first-in-class biparatopic antibody-drug conjugate (ADC) targeting a known tumor antigen.

Commenting one the news, Sam Murphy said: “Enrollment of the first patient in our Phase 2 clinical trial of JK07 is an important milestone in our heart failure program. Promising 6-month, Phase 1b data reported last year suggests that JK07 has the potential to improve heart function and long-term outcomes. We look forward to building on these promising findings and potentially delivering a new treatment option that can restore quality of life for heart failure patients.”